Gantenerumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Gantenerumab" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

2^nd place

2^nd place

3,257^th place

3,398^th place

1web.archive.org

1^st place

1^st place

195^th place

302^nd place

1semanticscholar.org

11^th place

8^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

7^th place

7^th place

ama-assn.org

"Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab" (PDF). American Medical Association.

clinicaltrials.gov

Clinical trial number NCT01760005 for "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)" at ClinicalTrials.gov

doi.org

Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, et al. (January 2018). "The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset". Expert Opinion on Biological Therapy. 18 (1): 25–35. doi:10.1080/14712598.2018.1389885. PMID 29037101. S2CID 4795458.
Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. (December 2017). "A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease". Alzheimer's Research & Therapy. 9 (1): 95. doi:10.1186/s13195-017-0318-y. PMC 5723032. PMID 29221491.

nih.gov

pubmed.ncbi.nlm.nih.gov

Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, et al. (January 2018). "The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset". Expert Opinion on Biological Therapy. 18 (1): 25–35. doi:10.1080/14712598.2018.1389885. PMID 29037101. S2CID 4795458.
Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. (December 2017). "A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease". Alzheimer's Research & Therapy. 9 (1): 95. doi:10.1186/s13195-017-0318-y. PMC 5723032. PMID 29221491.

ncbi.nlm.nih.gov

Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. (December 2017). "A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease". Alzheimer's Research & Therapy. 9 (1): 95. doi:10.1186/s13195-017-0318-y. PMC 5723032. PMID 29221491.

nytimes.com

Kolata G (10 February 2020). "An Alzheimer's Treatment Fails: 'We Don't Have Anything Now'". The New York Times.

semanticscholar.org

api.semanticscholar.org

Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, et al. (January 2018). "The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset". Expert Opinion on Biological Therapy. 18 (1): 25–35. doi:10.1080/14712598.2018.1389885. PMID 29037101. S2CID 4795458.

web.archive.org

"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization. Archived from the original (PDF) on 2012-02-11.

who.int

whqlibdoc.who.int

"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization. Archived from the original (PDF) on 2012-02-11.